Table 2.
Strategy | Cost (£) | % Eradication of H pylori | Cost of successful eradication (£) | Incremental cost of strategy 4 to strategies 1, 2, or 3 (£)* | Time (years) for future relapse treatment costs to equal incremental cost of strategy 4†
|
|
---|---|---|---|---|---|---|
Not discounted | Discounted‡ | |||||
1 | ||||||
OAM | 20.20 | 85 | 23.76 | 363.58 | 6.5 | 7.9 |
2 | ||||||
OCM | 29.20 | 91 | 32.08 | 589.59 | 10.6 | 15.7 |
3 | ||||||
OAM+UBT+OCM | 55.38 | 94 | 58.6 3 | 326.57 | 5.9 | 6.9 |
4 | ||||||
OCM+UBT+OCM | 62.63 | 97 | 64.78 | Base | Base | Base |
OAM=omeprazole, amoxycillin, and metronidazole; OCM=omeprazole, clarithromycin, and metronidazole; UBT=13C-urea breath test.
Additional cost of obtaining 1% increase in eradication rate.
Incremental cost of strategy 4 divided by annual cost (£55.60) of relapse treatment.
Future costs incurred after first year of eradication treatment discounted at 6% per year.